WANTED. Pharmacists to Help Patients Quit Smoking: Best practices and updates in cessation treatment. Robin Corelli, PharmD
|
|
- Sharlene Daniel
- 6 years ago
- Views:
Transcription
1 WANTED Pharmacists to Help Patients Quit Smoking: Best practices and updates in cessation treatment Robin Corelli, PharmD UCSF School of Pharmacy Karen Hudmon, DrPH, MS, RPh Purdue University College of Pharmacy
2 Target Audience: Pharmacists and Pharmacy Technicians ACPE#: L01-P/T Activity Type: Application-based
3 This activity is supported by an independent educational grant from Pfizer, Inc.
4 Disclosures Drs. Corelli and Hudmon declare no conflicts of interest, real or apparent, and no financial interests in any company, product, or service mentioned in this program, including grants, employment, gifts, stock holdings, and honoraria., The American Pharmacists Association is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
5 Learning Objectives At the completion of this application-based activity, participants will: 1. Summarize recent data regarding the safety and efficacy of available pharmacologic options for the treatment of tobacco use and dependence. 2. Discuss various approaches for use of cessation medications prior to the quit date. 3. Develop a treatment regimen that incorporates the most effective medications for smoking cessation, including medications doses, and routes and frequency of administration. 4. Explain the role of electronic nicotine delivery systems in quitting smoking.
6 Assessment Question #1 According to data from clinical trials, which of the following is most most effective for smoking cessation? A. Bupropion SR B. Electronic nicotine delivery systems (e.g., e-cigarettes) C. Nicotine replacement therapy D. Varenicline
7 Assessment Question #2 Which of the following smoking cessation medications has a boxed warning for serious neuropsychiatric side effects? A. Bupropion SR B. Varenicline C. A and B D. None of the above
8 Assessment Question #3 Which of the following nicotine replacement therapy formulations has the most compelling evidence for use prior to the quit date? A. Gum B. Inhaler C. Lozenge D. Patch
9 Assessment Question #4 Which of the following is the most appropriate combination therapy dosing for a patient who smokes one pack of cigarettes/day and smokes his first cigarette within 30 minutes of waking? A. 21 mg nicotine patch daily + 4 mg nicotine lozenge every 1-2h while awake B. 21 mg nicotine patch daily + 4 mg nicotine lozenge every 1-2h prn C. 21 mg nicotine patch + 14 mg nicotine patch daily D. 4 mg nicotine lozenge four times daily + nicotine nasal spray every 1-2h while awake
10 Assessment Question #5 Which of the following statement is TRUE regarding electronic nicotine delivery systems (ENDS; e.g., e- cigarettes)? A. ENDS are a safe alternative to cigarette smoking B. ENDS have lower exposure to carcinogens and toxins than tobacco smoke C. ENDS have a lower risk for nicotine dependence D. Electronic cigarettes are more effective than nicotine replacement therapy for quitting
11 The content for this session derives from the Rx for Change: Clinician-Assisted Tobacco Cessation program. Copyright The Regents of the University of California. All rights reserved.
12 CIGARETTE SMOKING is the chief, single, avoidable cause of death in our society and the most important public health issue of our time. C. Everett Koop, M.D., former U.S. Surgeon General
13 Tobacco Dependence: A 2-part problem Tobacco Dependence Physiological The addiction to nicotine Treatment Behavioral The habit of using tobacco Treatment Medications for cessation Behavior change program Treatment should address the physiological and the behavioral aspects of dependence.
14 Pharmacotherapy Clinicians should encourage all patients attempting to quit to use effective medications for tobacco dependence treatment, except where contraindicated or for specific populations* for which there is insufficient evidence of effectiveness. * Includes pregnant women, smokeless tobacco users, light smokers, and adolescents. Medications significantly improve success rates. Fiore et al. (2008). Treating Tobacco Use and Dependence: 2008 Update. Clinical Practice Guideline. Rockville, MD: USDHHS, PHS, May 2008.
15 First-Line Pharmacotherapies Nicotine gum Nicorette (OTC) Generic nicotine gum (OTC) Nicotine lozenge Commit (OTC) Generic nicotine lozenge (OTC) Transdermal nicotine patch NicoDerm CQ (OTC) Generic nicotine patches (OTC, Rx) Nicotine nasal spray Nicotrol NS (Rx) Nicotine oral inhaler Nicotrol (Rx) Bupropion SR tablets Zyban (Rx) Generic (Rx) Varenicline tablets Chantix (Rx) These are the only medications approved by the FDA for smoking cessation.
16 Timeline for Medications and Electronic Rx nicotine gum Nicotine Delivery Systems (ENDS) Rx transdermal nicotine patch 1991 Rx nicotine inhaler; Rx bupropion SR First e-cigarette made OTC nicotine lozenge Rx varenicline e-cigarettes sold in US 1984 OTC nicotine gum & patch; Rx nicotine nasal spray
17
18 Patient Cases
19 Case Presentations Brief description of case provided Discuss in groups of 2 or 3 Audience poll for recommended therapy regimen Data and discussion of treatment options Audience re-poll for recommended therapy regimen
20 Pharmacist s Patient Care Process Collect Ask about tobacco use and prior quit attempts Query patients regarding key issues Assess Readiness to quit Plan Facilitate quitting process; set a quit date Develop behavioral and pharmacologic treatment plan Implement Check for understanding and commitment to quit Follow-up: Monitor and Evaluate Monitor patient s progress throughout quit attempt
21 Case A: Greg Greg, 54 yo male with HTN, hyperlipidemia, depression, chronic rhinitis Current medications: Valsartan 80mg QAM for HTN Atorvastatin 40mg QAM for hyperlipidemia Bupropion XL 300mg QAM for depression Flonase (50mcg/spray), 1 spray in each nostril QAM for rhinitis Wants to quit in the next month; has joined a smoking cessation group program at work What questions do you want to ask Greg?
22 Key Considerations for Greg Tobacco use history: Current use: 25 cigarettes/day x 25 years; smokes within 20 min of waking Prior quit attempts: many, longest duration tobacco-free = 2 weeks Reasons for relapse: withdrawal, stress, after meals, other smokers Key issues for upcoming quit attempt: Reasons, motivation for wanting to quit: worsening CVD Confidence in ability to quit: high Other concerns: withdrawal symptoms during past quit attempt
23 Medication Selection for Greg Key considerations for medication selection: Previous failed quit attempts with monotherapy (patch, gum) Challenges adhering with complex regimens Currently taking bupropion XL 300mg daily for depression Concerned about side effects of varenicline Chronic rhinitis
24 Audience Poll #1 Which of the following treatment options is most appropriate for Greg? A. NRT monotherapy (gum, lozenge, patch, inhaler nasal spray) B. Combination NRT C. Bupropion SR D. Varenicline E. I don t know
25 OPTION #1: NRT Monotherapy Feature G L P I NS Available OTC Oral substitute for tobacco Relatively inexpensive* Long-acting; once daily dosing Used prn for nicotine withdrawal sx Used in combination with other NRTs G=gum; L=lozenge; P=patch; I=inhaler; NS=nasal spray * When compared to the cost of 1 pack of cigarettes/day ($6.17)
26 Long-Term Quit Rates: NRT Active drug Placebo 23.9 Percent quit Nicotine gum Nicotine patch Nicotine lozenge Nicotine nasal spray Nicotine inhaler Studies # Subjects 22,581 19,586 3, Data adapted from Stead et al. (2012). Cochrane Database Syst Rev.
27 Identify Key Issues to Streamline Product Selection Do you prefer a prescription or nonprescription medication? Would it be a challenge for you to take a medication frequently throughout the day (e.g., a minimum of 9 times)? With the exception of the nicotine patch, all NRT formulations require frequent dosing throughout the day. If patient is unable to adhere to the recommended dosing, these products should be ruled out as monotherapy because they will be ineffective. Ask these questions to reduce the time required for product selection. * Product-specific screening for warnings, precautions, contraindications, and personal preferences is also essential.
28 OPTION #2: Combination NRT Regimens with sufficient evidence to be recommended as first-line Combination NRT Long-acting formulation (patch) Produces relatively constant levels of nicotine PLUS Short-acting formulation (gum, lozenge*, inhaler, nasal spray) Allows for acute dose titration as needed for nicotine withdrawal symptoms *No combination data with lozenge were available when the CPG published Fiore et al. (2008). Treating Tobacco Use and Dependence: 2008 Update. Clinical Practice Guideline. Rockville, MD: USDHHS, PHS, May 2008.
29 Plasma Nicotine Concentrations 25 Cigarette Cigarette Plasma nicotine (mcg/l) Moist snuff Moist snuff Nasal spray Inhaler Lozenge (2mg) Gum (2mg) Patch 0 1/0/ /10/ /20/1900 1/30/1900 2/9/ /19/ /29/ Time (minutes)
30 Multiple Treatment Comparison Meta-Analysis Comparison Odds ratio (95% CI) Nicotine gum vs Placebo 1.7 ( ) Nicotine patch vs Placebo 1.9 ( ) Other NRT* vs Placebo 2.0 ( ) Combination NRT vs Placebo 2.7 ( ) *Includes nicotine nasal spray, lozenge, and inhaler Strong evidence that combination NRT is more effective than NRT monotherapy Cahill et al. (2013). Cochrane Database Syst Rev 5:CD
31 Combination NRT: Recommended Regimens Nicotine patch Dose: 21 mg/day x 4 6 wks 14 mg/day x 2 wks 7 mg/day x 2 wks PLUS Nicotine gum or lozenge (2 mg/4 mg; based on TTFC) Dose: Use 1 piece every 1 2 hours prn (use at least 4-5/day) OR Nicotine inhaler Dose: Use 1 cartridge (10 mg) every 1 2 hours prn OR Nicotine nasal spray Dose: Use 1 spray (0.5 mg) in each nostril every 1 2 hours prn
32 Combination NRT: Recommended Regimens Nicotine patch Dose: 21 mg/day x 4 6 wks 14 mg/day x 2 wks 7 mg/day x 2 wks PLUS Nicotine gum X or lozenge (2 mg/4 mg; based on TTFC) Dose: Use 1 piece every 1 2 hours prn (use at least 4-5/day) OR Nicotine inhaler Dose: Use 1 cartridge (10 mg) every 1 2 hours prn OR Nicotine nasal Xspray Dose: Use 1 spray (0.5 mg) in each nostril every 1 2 hours prn
33 OPTION #3: Bupropion SR Available for cessation: 150 mg tablets Considerations for Greg: Ease of use, twice-daily oral tablet Can be used in combination with NRT No medical history precluding use Might be beneficial in patients with depression Still smoking while on 300mg XL daily Dosing approaches Usual dose: 150mg every morning x 3 days, then 150mg twice daily x 7-12 weeks
34 OPTION #4: Varenicline Available for cessation: 0.5 and 1.0 mg tablets Considerations for Greg: Ease of use, twice-daily oral tablet Neuropsychiatric side effects in patients with psychiatric disorders Recent safety data for varenicline versus other agents (Anthenelli et al., 2016) Dosing approaches: Usual dose, with: Fixed Quit Flexible Quit Gradual Quit Anthenelli RM et al. Lancet 2016;387:
35 Varenicline: Standard Dosing Patients should begin therapy 1 week PRIOR to their quit date. The dose is gradually increased to minimize treatment-related nausea and insomnia. Initial dose titration Treatment Day Day 1 to day 3 Day 4 to day 7 Day 8 to end of treatment* Dose 0.5 mg daily 0.5 mg twice daily 1 mg twice daily * Up to 12 weeks, with an option to continue treatment in select patients.
36 Varenicline Quit Approaches FIXED QUIT approach Set quit date for 1 week after starting varenicline Continue treatment for 12 weeks FLEXIBLE QUIT approach Start taking varenicline and pick a quit date between 8 to 35 days from treatment initiation Continue treatment for 12 weeks GRADUAL QUIT approach Start taking varenicline and reduce smoking by 50% within the first 4 weeks, an additional 50% in the next 4 weeks, and continue until complete abstinence by 12 weeks Images from:
37 Multiple Treatment Comparison Meta-Analysis Comparison Odds ratio (95% CI) Nicotine gum vs Placebo 1.7 ( ) Bupropion SR vs Placebo 1.9 ( ) Nicotine patch vs Placebo 1.9 ( ) Other NRT* vs Placebo 2.0 ( ) Combination NRT vs Placebo 2.7 ( ) Varenicline vs Placebo 2.9 ( ) *Includes nicotine nasal spray, lozenge, and inhaler Strong evidence that varenicline is more effective than other monotherapies Cahill et al. (2013). Cochrane Database Syst Rev 5:CD
38 Selecting a Regimen for Greg INSERT TRIGGER TAPE Video (~5 seconds long) Male patient stating Chantix? Isn t that the drug that has all those horrible side effects?
39 Anthenelli RM et al. Lancet 2016;387:
40 Varenicline and Bupropion SR: Safety Update FDA-mandated clinical trial 24-week, double-blind; active and placebo-controlled: Varenicline: standard dosing, 12 weeks Bupropion SR: standard dosing, 12 weeks Nicotine patch: 21 mg/day with standard taper, 12 weeks Placebo, 12 weeks All arms: 13 counseling visits, 11 telephone calls Follow-up through 24 weeks Outcome = continuous abstinence Anthenelli RM et al. Lancet 2016;387:
41 Varenicline and Bupropion SR: Safety Update (cont d) Incidence of Moderate or Severe Neuropsychiatric Adverse Events Patient cohort Varenicline Bupropion SR Nicotine patch Placebo Non-psychiatric 1.3% 2.2% 2.5% 2.4% Psychiatric 6.5% 6.7% 5.2% 4.9% Anthenelli RM et al. Lancet 2016;387: No significant differences in neuropsychiatric events by treatment arm
42 Treatment arms: Efficacy (Weeks 9-24) Continuous Abstinence Patient cohort Varenicline Bupropion SR Nicotine patch Placebo Non-psychiatric 25% 19% 18% 11% Psychiatric 18% 14% 13% 8% Anthenelli RM et al. Lancet 2016;387: Highest efficacy with varenicline
43
44 Audience Poll #2 Which of the following treatment options is most appropriate for Greg? A. Nicotine patch B. Short-acting NRT (gum, lozenge, inhaler, nasal spray) C. Combination NRT D. Varenicline E. I don t know
45 Summary of Therapy Options: Greg Preferred Options: Combination NRT (patch + short-acting formulation) Varenicline Less Preferred Option: NRT monotherapy with patch Inappropriate Options: NRT monotherapy (gum, lozenge, inhaler, nasal spray) Bupropion SR
46 14-day Follow-up with Greg INSERT TRIGGER TAPE Video (~15 seconds long) Male patient stating Thanks for following up, I really appreciate it. [pause] Yeah, I m doing better than I thought I would. Haven t had a cigarette in a week. [nod] Yep Yep Nope not really any issues other than I ve been having a hard time sleeping. Do you think that s the Chantix? What questions do you want to ask Greg?
47 Audience Poll #3 Which of the following might be contributing to Greg s insomnia? (check all that apply) A. Drug interaction between tobacco smoke and caffeine B. Wellbutrin XL C. Varenicline D. Nicotine withdrawal symptoms E. I don t know
48 Drug Interaction: Tobacco Smoke and Caffeine Constituents in tobacco smoke induce CYP1A2 enzymes, which metabolize caffeine Caffeine levels increase ~56% upon quitting Nicotine withdrawal effects might be enhanced by increased caffeine levels Decrease caffeine intake by 50% when quitting; no caffeine after 1PM for normal sleep/wake cycle Interaction is due to combustion products of tobacco, NOT nicotine.
49 Nicotine Withdrawal Effects Irritability/frustration/anger Anxiety Difficulty concentrating Restlessness/impatience Depressed mood/depression Insomnia Impaired performance Increased appetite/weight gain Cravings Most symptoms manifest within the first 1 2 days, peak within the first week, and subside within 2 4 weeks. Hughes. (2007). Nicotine Tob Res 9:
50 Case B: Natalie 37 yo, presenting with chronic respiratory symptoms x 6 mo; productive cough, SOB, decreased exercise tolerance Current meds: hormonal contraception (NuvaRing) PCP has strongly encouraged smoking cessation to manage respiratory symptoms No health insurance; concerned about costs of quitting What questions do you want to ask Natalie?
51 Pharmacist s Patient Care Process Collect Ask about tobacco use and prior quit attempts Query patients regarding key issues Assess Readiness to quit Plan Facilitate quitting process; set a quit date Develop behavioral and pharmacologic treatment plan Implement Check for understanding and commitment to quit Follow-up: Monitor and Evaluate Monitor patient s progress throughout quit attempt
52 Key Considerations for Natalie Key points to consider for medication selection: 20 cig/day, smokes within 10 min of waking Multiple failed quit attempts: hypnosis, acupuncture, cold turkey; no prior cessation medications or behavioral counseling History of bulimia in high school Female >35 yo on HC (increased risk) Interested in ENDS for cessation Has friend who used ENDS and decreased from 1 pack to ¼ pack per day
53 Audience Poll #4 Which of the following treatment options is most appropriate for Natalie? A. NRT initiated BEFORE the quit date B. Varenicline C. Bupropion SR D. Electronic nicotine delivery system E. I don t know
54 OPTION #1: Nicotine Patch Initiated Before the Quit Date Pre-Quit NRT ( nicotine preloading ) Use of NRT before the quit date (e.g., while smoking) Rationale Smoking while using NRT might reduce the reinforcing effects of inhaled nicotine from smoking Abrupt cessation and medication initiation problematic Early exposure to NRT can allow for (1) early dosage adjustment; (2) familiarity with the product; (3) enhanced confidence as the quit date approaches Concerns Potential for additive nicotine toxicity
55 Pre-Quit Initiation of NRT: Summary of Evidence Published RCTs (n=8*; >2,700 subjects) Baseline characteristics of study subjects Motivated to quit smoking Heavier smokers (mean, 25 CPD; range, 19-30) Pooled results show a modest but non-significant increase in quit rates with pre-quit NRT (RR 1.18, 95% CI ) Analysis of nicotine patch trials suggests a more pronounced response (RR 1.34, 95% CI ) Well tolerated no significant differences in SEs observed *NRT included patch (6 studies), lozenge (1 study), gum (1 study) Stead et al. (2012). Cochrane Database Syst Rev 11:CD
56 Rose et al. (2009). Nicotine Tob Res 11:
57 Nicotine Patch Initiated Before the Quit Date Percent quit Effect of pre-cessation nicotine patch use on long-term quit rates Nicotine patch (21 mg) x 2 weeks pre-quit Placebo patch x 2 weeks pre-quit p=0.03 at 6 months Weeks post-quit day Rose et al. (2009) Nicotine Tob Res 11:
58 Pre-Quit Initiation of NRT: Practical Considerations Limited evidence; not a routine first-line recommendation Most compelling evidence is with the patch formulation Treatment started 2 weeks before quit date (range, 2-4 weeks) Evidence for short-acting NRT is limited and unconvincing Gum and lozenge: not effective Nasal spray and inhaler: not studied Reserve for patients: With low confidence in medications (NRT) Working with smoking cessation specialists
59 OPTION #2: Varenicline Percent Considerations for Natalie: Ease of use, twice-daily oral tablet High efficacy No medical history precluding use Cost Varenicline vs placebo (n=27; 12,625 pts) Long-Term (>6 months) Quit Rates Varenicline vs bupropion SR (n=5; 5,877 pts) n=24,766 Varenicline vs NRT (n=5; 6,264 pts) Cahill et al. (2016). Cochrane Database Syst Rev 5:CD
60 Varenicline: Pros and Cons Pros Effective; 3-fold higher long-term quit rates vs. placebo Twice daily dosing; improved adherence Cons Screening and monitoring necessary for serious adverse effects Neuropsychiatric events Nausea / insomnia Cost
61 Comparative Daily Costs of Pharmacotherapy $16 $14 Average $/pack of cigarettes, $6.17 $12 $10 $/day $8 $6 $4 $2 $0 Bupropion Gum Lozenge Patch Nasal spray Inhaler SR Varenicline Trade $3.60 $3.60 $2.90 $7.99 $13.62 $8.25 $13.84 Generic $1.90 $3.33 $1.52 $ Wholesale acquisition cost from Red Book Online. Thomson Reuters, December Campaign for Tobacco-Free Kids. (2017). State Cigarette Excise Tax Rates & Rankings. Retrieved December 9, 2017, from
62 OPTION #3: Bupropion SR Pros Effective; 2-fold higher long-term quit rates vs. placebo Twice daily dosing; improved adherence Generic formulations available; less expensive Cons History of bulimia precludes use Screening and monitoring necessary for serious adverse effects Neuropsychiatric events Seizures
63 Bupropion SR: Contraindications, Warnings, and Precautions for Use Boxed Warning Increased risk of suicide in children, adolescents, and young adults Contraindications Seizure disorder Current or prior diagnosis of bulimia or anorexia nervosa Co-treatment with MAO inhibitors Known hypersensitivity to bupropion Warnings & Precautions Neuropsychiatric AEs and suicide risk in smoking cessation treatment Seizures (dose-related, other risk factors) Hypertension Psychosis and other neuropsychiatric reactions Angle closure glaucoma Hypersensitivity reactions GlaxoSmithKline Inc. (2017, May). Zyban Package Insert. Research Triangle Park, NC.
64 Bupropion SR: Seizure Prevalence in Clinical Trials Indication Dose (formulation) Seizures (n/n) % Bulimia mg TID (IR) 4/ Depression mg/day divided TID (IR) 13/3, Depression mg twice daily (SR) 3/3, Smoking cessation mg twice daily (SR) 6/5, IR= immediate-release; SR= sustained-release 1 Horne et al., J Clin Psychiatry (1988); 2 Johnston et al., J Clin Psychiatry (1991); 3 Dunner et al., J Clin Psychiatry (1998); 4 Hughes et al., Cochrane Database Syst Rev (2014)
65 OPTION #4: Electronic Nicotine Delivery System Devices similar in appearance to cigarettes, cigars, pipes, or pens Battery-operated devices that create a vapor for inhalation Simulates smoking but does not involve combustion of tobacco Also known as: E-cigarette, E-hookah, Hookah pen Vapes, Vape pen, Vape pipe Mods Images from Grana et al.,
66 ENDS for Cessation: Current Evidence Data from RCTs suggests ENDS are well-tolerated during short-term use Quality control for many products is lacking; consumers do not have reliable product information Adverse health effects associated with second-hand vapor exposure cannot be excluded Nicotine in ENDS solutions increases the risk of accidental poisoning Carcinogenic substances are present in some aerosols Battery safety concerns (e.g., overheating, fires, explosions), primarily with tank-models, pose additional health risks Health effects of long-term, regular use are unknown
67 ENDS for Cessation: Recommendations for Clinicians Assess ENDS use along with tobacco use during clinical encounters Actively discourage ENDS use in current non-smokers Until more is known about the potential risks, ENDS should not be promoted as a safe alternative to smoking ENDS have not been proven to be effective for cessation Until long-term efficacy data are available, clinicians should recommend evidence-based, FDA-approved treatments for smoking cessation
68 ENDS for Cessation: Recommendations for Clinicians (cont d) Evidence suggests that ENDS use is less harmful than smoking Potentially increased risk with dual use (tobacco + ENDS) ENDS might have a role in patients who are unable to quit smoking using proven methods Weigh risks and benefits on a case-by-case basis Currently, ENDS are unregulated; most contain low toxic constituents (in lower concentrations compared to tobacco smoke) Advise patients to quit smoking entirely even low levels of smoking impose significant health risks
69 ENDS: Risks of Dual Use with Cigarettes Health Consequences of Light Smoking Smoking 1-4 cigarettes/day is associated with significantly higher risk of dying from ischemic heart disease (both sexes) and lung cancer (females) 1 Light and intermittent smoking carry nearly the same risk for cardiovascular disease as does daily smoking 2 Light smokers (1-10 cigarettes/day) have higher all-cause mortality risk than do never smokers 3 There is no risk-free level of exposure to tobacco smoke 1 Bjartveir & Tverdal, Tobacco Control (2005); 2 Schane et al., Circulation (2010); 3 Inoue-Choi et al, JAMA Int Med (2017)
70 U.S. Position The current evidence is insufficient to recommend electronic nicotine delivery systems (ENDS) for tobacco cessation. Clinicians should direct patients who smoke tobacco to other cessation interventions with established effectiveness and safety. Tobacco Smoking Cessation in Adults, Including Pregnant Women: Behavioral and Pharmacotherapy Interventions. U.S. Preventive Services Task Force, September 2015.
71 Summary of Therapy Options: Natalie Preferred Option: Varenicline Less Preferred Option: NRT patch (initiated before the quit date) Inappropriate Options: Bupropion SR Electronic nicotine delivery systems Short-acting NRT (initiated before the quit date)
72 Drugs don t work in patients who don t take them. C. Everett Koop, M.D., former U.S. Surgeon General Medication adherence should be assessed at each encounter.
73 Key Take-Home Points Many options currently exist for treatment of tobacco use and dependence. Treatment should consist of behavioral counseling in combination with one or more medications for cessation (when not contraindicated). The most effective monotherapy medication is varenicline. Combination nicotine replacement therapy has comparable efficacy as varenicline. ENDS are not currently recommended for cessation. Treatment selection should be patient-specific.
74 Contact Information Robin Corelli, PharmD UCSF School of Pharmacy Karen Hudmon, DrPH, MS, RPh Purdue University College of Pharmacy
75 Assessment Question #1 According to data from clinical trials, which of the following is most most effective for smoking cessation? A. Bupropion SR B. Electronic nicotine delivery systems (e.g., e-cigarettes) C. Nicotine replacement therapy D. Varenicline
76 Assessment Question #2 Which of the following smoking cessation medications has a boxed warning for serious neuropsychiatric side effects? A. Bupropion SR B. Varenicline C. A and B D. None of the above
77 Assessment Question #3 Which of the following nicotine replacement therapy formulations has the most compelling evidence for use prior to the quit date? A. Gum B. Inhaler C. Lozenge D. Patch
78 Assessment Question #4 Which of the following is the most appropriate combination therapy dosing for a patient who smokes one pack of cigarettes/day and smokes his first cigarette within 30 minutes of waking? A. 21 mg nicotine patch daily + 4 mg nicotine lozenge every 1-2h while awake B. 21 mg nicotine patch daily + 4 mg nicotine lozenge every 1-2h prn C. 21 mg nicotine patch + 14 mg nicotine patch daily D. 4 mg nicotine lozenge four times daily + nicotine nasal spray every 1-2h while awake
79 Assessment Question #5 Which of the following statement is TRUE regarding electronic nicotine delivery systems (ENDS; e.g., e- cigarettes)? A. ENDS are a safe alternative to cigarette smoking B. ENDS have lower exposure to carcinogens and toxins than tobacco smoke C. ENDS have a lower risk for nicotine dependence D. Electronic cigarettes are more effective than nicotine replacement therapy for quitting
Welcome Please stand by. We will begin shortly.
Welcome Please stand by. We will begin shortly. Beyond the Basics: Pharmacotherapy for Smoking Cessation Monday, March 14, 2016 1pm ET (120 minutes) Disclosure Dr. Robin L. Corelli, Dr. Karen S. Hudmon,
More informationQuitting for Good: A Tobacco Treatment Workshop for Community Pharmacists
Quitting for Good: A Tobacco Treatment Workshop for Community Pharmacists Robin L. Corelli, PharmD, TTS UCSF School of Pharmacy Karen S. Hudmon, DrPH, MS, RPh, TTS Purdue College of Pharmacy Annual Meeting
More informationLearning Objectives 4/3/2018 UP IN SMOKE: NAVIGATING THE CHANGING LANDSCAPE OF SMOKING CESSATION BACKGROUND
UP IN SMOKE: NAVIGATING THE CHANGING LANDSCAPE OF SMOKING CESSATION Richard Dang, PharmD, APh, BCACP Assistant Professor of Clinical Pharmacy, USC School of Pharmacy Rory Kim, PharmD, BCACP Assistant Professor
More informationMedication Management to Aid in Smoking Cessation. Rachel Constant, Pharm.D. Baptist Health Corbin Pharmacy Resident 3/22/2019
Medication Management to Aid in Smoking Cessation Rachel Constant, Pharm.D. Baptist Health Corbin Pharmacy Resident 3/22/2019 1 Learning Objectives: Review the prevalence of tobacco use. Describe tools
More informationPharmacotherapy for Treating Tobacco Dependence
Pharmacotherapy for Treating Tobacco Dependence Sheila K. Stevens, MSW Education Coordinator Nicotine Dependence Center 2013 MFMER slide-1 Rationale for Pharmacological Therapy Success rate doubles Manage
More informationPharmacologic Therapy for Tobacco Use & Dependence
Pharmacologic Therapy for Tobacco Use & Dependence Thomas Gauvin, MA, TTS Mayo Clinic Nicotine Dependence Center Rochester, MN 2013 MFMER slide-1 Learning Objectives Understand the 7 first line medications
More informationWelcome Please stand by. We will begin shortly.
Welcome Please stand by. We will begin shortly. Integrating Medications into Smoking Cessation Treatment: The Basics Tuesday, September 22, 2015 2pm ET (90 minutes) Disclosure Dr. Robin L. Corelli, Dr.
More informationEffective Treatments for Tobacco Dependence
Effective Treatments for Tobacco Dependence Abigail Halperin MD, MPH Director, University of Washington Tobacco Studies Program Ken Wassum Associate Director of Clinical Development and Support Quit for
More informationNYSMPEP Smoking Cessation Guidance: Key Message 3
NYSMPEP Smoking Cessation Guidance: Key Message 3 Key Message 3: All smokers trying to quit should be offered medication (except when contraindicated or for specific populations). The Agency for Healthcare
More informationMy Mask. I keep it all inside. Because I d rather. The pain destroy me. Than everyone else. Anon.
My Mask KL I keep it all inside Because I d rather The pain destroy me Than everyone else. Anon. 43 K. N. Roy Chengappa, M.D., FRCPC Professor of Psychiatry, University of Pittsburgh School of Medicine,
More informationCessation Medicine Reference Guide Table of Contents
Cessation Medicine Reference Guide Table of Contents 1. Patch 2. Nicotine Gum 3. Nicotine Lozenge 4. Inhaler 5. Nasal Spray 6. Bupropion SR (Zyban) 7. Chantix (Varenicline) Patch Typical course of therapy
More informationTobacco Dependence Screening and Treatment in Behavioral Health Settings. Prescribing
Tobacco Dependence Screening and Treatment in Behavioral Health Settings Prescribing GOAL To build the capacity of prescribing clinicians in behavioral health settings to integrate best practices for prescribing
More informationMEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Smoking Cessation Products LAST REVIEW 5/8/2018 THERAPEUTIC CLASS: Psychiatric Disorders REVIEW HISTORY 5/17, 5/16, 5/15,
More informationSmoking Cessation: Where Are We Now? Nancy Rigotti, MD
Smoking Cessation: Where Are We Now? Nancy Rigotti, MD Director, MGH Tobacco Research and Treatment Center Professor of Medicine, Harvard Medical School nrigotti@partners.org OVERVIEW The challenge for
More informationBackground. Abstinence rates associated with varenicline
What are the range of abstinence rates for varenicline for smoking cessation? Do they differ based on treatment duration? Are there any studies utilizing 3-4 months of varenicline treatment? Background
More informationAIDS for CESSATION PHARMACOTHERAPY. METHODS for QUITTING. NONPHARMACOLOGIC METHODS (cont d) NONPHARMACOLOGIC METHODS
METHODS for QUITTING AIDS for CESSATION Nonpharmacologic Counseling and other non-drug approaches Pharmacologic FDA-approved medications Counseling and medications are both effective, but the combination
More informationTobacco Cessation: Priority for Health Providers. Acknowledgements. Tobacco Cessation: Secondhand Smoke. Smoke-Free Environment & CA
Acknowledgements Smoking Cessation Leadership Center http://smokingcessationleadership.ucsf.edu/ Rx for Change http://rxforchange.ucsf.edu/ Tobacco Use and Dependence: 2008 Update http://www.surgeongeneral.gov/tobacco
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2045-6 Program Prior Authorization/HCR- Tobacco Cessation - Health Care Reform Medication Bupropion SR (generic Zyban), Chantix
More informationIMPORTANT POINTS ABOUT MEDICATIONS
IMPORTANT POINTS ABOUT MEDICATIONS The U.S. Food & Drug Administration (FDA) advises that there are significant health benefits to quitting smoking. The health benefits of quitting smoking include a reduction
More informationTOBACCO CESSATION: INCORPORATING MOTIVATIONAL INTERVIEWING AND EXAMINING THE ROLE OF E-CIGS
Learning Objectives TOBACCO CESSATION: INCORPORATING MOTIVATIONAL INTERVIEWING AND EXAMINING THE ROLE OF E-CIGS Cheyenne Newsome, PharmD PGY2 Ambulatory Care Resident University of New Mexico College of
More informationTOBACCO CESSATION: INCORPORATING MOTIVATIONAL INTERVIEWING AND EXAMINING THE ROLE OF E-CIGS
TOBACCO CESSATION: INCORPORATING MOTIVATIONAL INTERVIEWING AND EXAMINING THE ROLE OF E-CIGS Cheyenne Newsome, PharmD PGY2 Ambulatory Care Resident University of New Mexico College of Pharmacy Learning
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2018 P 4005-2 Program Health Care Reform Tobacco Cessation Supply Limit (Therapy Duration) Override Kentucky Fully Insured Medication
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Reference Number: CP.CPA.113 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important regulatory
More informationThe Role of Pharmacy in Providing Pharmacotherapy for Tobacco Cessation Karen S. Hudmon, DrPH, MS, RPh
The Role of Pharmacy in Providing Pharmacotherapy for Tobacco Cessation Karen S. Hudmon, DrPH, MS, RPh Professor of Pharmacy Practice Purdue University College of Pharmacy Why (or Why Not) a Pharmacist?
More informationPharmacotherapy Safety and Efficacy in Adolescent Smoking Cessation
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2011 Pharmacotherapy Safety and Efficacy in
More informationAsk-Advise-Refer Brief Interventions for Assisting Patients with Quitting
Ask-Advise-Refer Brief Interventions for Assisting Patients with Quitting TRAINING OVERVIEW Epidemiology of Tobacco Use Addiction to Nicotine Medications for Smoking Cessation Changing Behavior Referring
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Policy: Smoking Cessation Products Reference Number: TCHP.PHAR.18002 Effective Date: 01.01.19 Last Review Date: 10.12.18 Line of Business: Oregon Health Plan Revision Log See Important Reminder at the
More informationSmoking cessation therapy
Appendix 1 Smoking cessation therapy Q. Can a dentist prescribe medications for smoking cessation? A. Yes. Dentists are allowed and are encouraged to help patients with smoking cessation by counseling
More informationRegistered Nurses Referral to Quitlines: Helping Smokers Quit (RNQL HSQ) in Louisiana
Rx for change Registered Nurses Referral to Quitlines: Helping Smokers Quit (RNQL HSQ) in Louisiana Linda Sarna, RN, PhD, FAAN UCLA School of Nursing Stella Aguinaga Bialous, RN, DrPH, FAAN Tobacco Policy
More informationQuit (RNQL-HSQ) in Louisiana
Rx for change Registered Nurses Referral to Quitlines: Helping Smokers Quit (RNQL-HSQ) in Louisiana Linda Sarna, RN, PhD, FAAN UCLA School of Nursing Stella Aguinaga Bialous, RN, DrPH, FAAN Tobacco Policy
More informationIs Vaping a Valid Strategy for Smoking Cessation? Myths and Facts Jaspreet S. Brar. MD, PhD Community Care Behavioral Health Organization
Is Vaping a Valid Strategy for Smoking Cessation? Myths and Facts Jaspreet S. Brar. MD, PhD Learning Objectives What are e-cigarettes and vapes? Myths and Facts related to vaping Vaping for harm reduction
More informationSMOKING CESSATION WORKSHOP. Dr Mark Palayew December
SMOKING CESSATION WORKSHOP Dr Mark Palayew December 5 2016 Conflicts of Interest None Case 1 Mr. T is a 55 year old smoker 2 packs/day He has been smoking continuously since age 16 When he wakes up at
More informationChantix Label Update 2018
Chantix Label Update 2018 Chantix (varenicline) Prescribing Information Chantix Prescribing Info URL and Disclaimer Please refer to the full Prescribing Information on important treatment considerations
More informationClearing the Air: What You Need to Know and Do to Prepare to Quit Smoking
Clearing the Air: What You Need to Know and Do to Prepare to Quit Smoking Getting Ready to Quit Course Creating Success! THINK ABOUT Process of Changing an Addiction Your Pros and Cons of Smoking and Quitting
More informationOutpatient Tobacco Addiction Treatment Pathway Additional Notes
Outpatient Tobacco Addiction Treatment Pathway Additional Notes First Line: Varenicline (provide in conjunction with counselling/support, but if such support is refused or is not available, this should
More informationTreating Tobacco Use:
Treating Tobacco Use: Optimizing for the Best Outcomes Nancy Rigotti, MD Director, MGH Tobacco Research and Treatment Center Professor of Medicine, Harvard Medical School nrigotti@partners.org Primary
More informationPharmacological Treatments for Tobacco Users with Behavioral Health Conditions
Pharmacological Treatments for Tobacco Users with Behavioral Health Conditions Jill M Williams, MD Professor Psychiatry Director, Division Addiction Psychiatry Robert Wood Johnson Medical School Disclosures
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2018 P 2045-9 Program Prior Authorization/HCR- Tobacco Cessation - Health Care Reform Medication Bupropion SR (generic Zyban), Chantix
More informationPharmacotherapy for Tobacco Dependence Treatment
Pharmacotherapy for Tobacco Dependence Treatment Nancy Rigotti, MD Professor of Medicine, Harvard Medical School Director, Tobacco Research and Treatment Center, Massachusetts General Hospital nrigotti@partners.org
More informationPHARMACOTHERAPY OF SMOKING CESSATION
PHARMACOTHERAPY OF SMOKING CESSATION Domenic A. Ciraulo, MD Director of Alcohol Pharmacotherapy Research Center for Addiction Medicine Department of Psychiatry Massachusetts General Hospital Disclosure
More informationSmoke-free Hospitals. Linda A. Thomas, MS University of Michigan Health System Tobacco Consultation Service
Smoke-free Hospitals Linda A. Thomas, MS University of Michigan Health System Tobacco Consultation Service Today s Subjects 5A s and Clinician Training and Use with the Hospitalized Patient NRT use in
More informationSmoking Cessation Services Guidance
Smoking Cessation Services Guidance Alabama Medicaid Tobacco Treatment Coverage Covered Services/Medication 1. Free tobacco cessation counseling is provided through the Alabama Tobacco Quitline. Refer
More informationSmoking Cessation and the Pharmacist
Smoking Cessation and the Pharmacist Jennifer Roberts Assistant Director, Research Pharmacy 1 Objectives Review smoking cessation medication use, based on public health guidelines, as well as contraindications
More information3. Chantix [package insert]. New York, NY: Pfizer, Inc,; Ramon JM, Morchon S, Baena A, Masuet-Aumatell C. Combining varenicline and nicotine
How can there be a warning regarding concomitant use of varenicline with nicotine replacement therapy yet patients can be on varenicline and smoke concurrently? April 20, 2017 The United States (US) Preventive
More information5. Offer pharmacotherapy to all smokers who are attempting to quit, unless contraindicated.
0 11 Key Messages 1. Ask and document smoking status for all patients. 2. Provide brief advice on quit smoking at every visit to all smokers. 3. Use individual, group and telephone counselling approaches,
More informationHelping People Quit Tobacco
Helping People Quit Tobacco Peter Selby MBBS, CCFP, MHSc, ASAM Associate Professor, University of Toronto Clinical Director, Addictions Program, CAMH Principal Investigator, OTRU Disclosures! Grants/research
More informationTobacco Cessation, E- Cigarettes and Hookahs
Objectives Tobacco Cessation, E- Cigarettes and Hookahs Discuss evidence-based tobacco cessation interventions including pharmacologic options. Review e-cigarette and hookah facts and safety considerations.
More informationAIDS for CESSATION PHARMACOTHERAPY. METHODS for QUITTING. NONPHARMACOLOGIC METHODS (cont d) NONPHARMACOLOGIC METHODS
METHODS for QUITTING AIDS for CESSATION Nonpharmacologic Counseling and other non-drug approaches Pharmacologic FDA-approved medications Counseling and medications are both effective, but the combination
More informationPharmacotherapy Summary for the Treatment of Nicotine Withdrawal and Nicotine Dependence 1
Pharmacotherapy Summary for the Treatment of Nicotine Withdrawal and Nicotine Dependence 1 Compiled by: TOP, in collaboration with Dr. Charl Els and Mr. Ron Pohar: TRaC II (Alberta Medical Association/Primary
More informationTreatment of Nicotine Dependence: a brief review
Treatment of Nicotine Dependence: a brief review James Morrill, MD, PhD MGH Charlestown HealthCare Center Massachusetts General Hospital Disclosure Neither I nor my spouse/partner has a relevant financial
More informationTobacco Use Dependence and Approaches to Treatment
University of Kentucky UKnowledge Nursing Presentations College of Nursing 11-2011 Tobacco Use Dependence and Approaches to Treatment Audrey Darville University of Kentucky, audrey.darville@uky.edu Chizimuzo
More informationEVIDENCE-BASED INTERVENTIONS TO HELP PATIENTS QUIT TOBACCO
EVIDENCE-BASED INTERVENTIONS TO HELP PATIENTS QUIT TOBACCO Lena Matthias Gray, MSA, CTTS-M University of Michigan MHealthy Tobacco Consultation Service Overview of Tobacco Use The World Health Organization
More informationBest Practice for Smoking Cessation: Pharmacotherapy. Emma Dean Acting Population Health and Health Promotion Coordinator Lead Pharmacist- Smokefree
Best Practice for Smoking Cessation: Pharmacotherapy Emma Dean Acting Population Health and Health Promotion Coordinator Lead Pharmacist- Smokefree Why is it so hard to quit? People who smoke aren t weak
More informationCURRENT ISSUES IN TOBACCO CESSATION FOR THE PRACTICING PHYSICIAN
CURRENT ISSUES IN TOBACCO CESSATION FOR THE PRACTICING PHYSICIAN Shahnaz Fatteh, M.D. Associate Clinical Professor and Director, Asthma, Allergy and Immunology Clinic Dr. Kiran C. Patel College of Osteopathic
More informationTobacco Cessation: Best Practices in Cancer Treatment. Audrey Darville, PhD APRN, CTTS Certified Tobacco Treatment Specialist UKHealthCare
Tobacco Cessation: Best Practices in Cancer Treatment Audrey Darville, PhD APRN, CTTS Certified Tobacco Treatment Specialist UKHealthCare Objectives 1. Describe the current state of tobacco use treatment
More information7 DAY QUIT SMOKING CHALLENGE 7 DAY QUIT SMOKING CHALLENGE 7 DAY QUIT SMOKING PDF YOU CAN QUIT SMOKING. QUIT SMOKING CDC 1 / 5
7 DAY QUIT SMOKING PDF YOU CAN QUIT SMOKING. QUIT SMOKING CDC 1 / 5 2 / 5 3 / 5 7 day quit smoking pdf 7 Your guide to quitting smoking This guide is for smokers who want to quit and stay quit. Just like
More informationTRENDS IN TOBACCO UNDERSTAND 5/26/2017 LEARNING OBJECTIVES. Understand the types of tobacco products trending in today s market & associated risks
TRENDS IN TOBACCO And What Employers Can Do to Support Cessation Katy Tombaugh, Certified Tobacco Treatment Specialist Founder & CEO, Wellness Collective LEARNING OBJECTIVES Understand the types of tobacco
More informationHIV and Aging. Making Tobacco Cessation a Priority in HIV/AIDS Services. Objectives. Tobacco Use Among PLWHA
HIV and Aging Making Tobacco Cessation a Priority in HIV/AIDS Services June 27, 2008 Amanda Brown, MPH Ruth Tripp, MPH, RN Objectives To explore existing knowledge of the HIV and smoking connection. To
More informationTreatment of Tobacco Dependence
Treatment of Tobacco Dependence Shamim Nejad MD Swedish Cancer Institute Swedish Medical Center Shamim.Nejad@swedish.org Case: Nancy D. 55 year old woman with right breast cancer, s/p chemoradiation and
More informationOver the Road Truck Driver Who Smokes
Continuing Medical Education Case Presentation 1 CME Credit Physicians Physician Assistants Nurse Practitioners Over the Road Truck Driver Who Smokes RELEASE & REVIEW DATE This activity was last reviewed
More informationLinda Sarna, RN, DNSc, FAAN. Marjorie Wells, PhD, RN, FNP
Helping Smokers Quit: Indiana Linda Sarna, RN, DNSc, FAAN Stella Aguinaga Bialous, RN, DrPH, FAAN Marjorie Wells, PhD, RN, FNP From Guideline to Practice: A Nursing Intervention to Help Smokers Quit Funded
More informationAn Evolving Perspective on Smoking Cessation Therapies
An Evolving Perspective on Smoking Cessation Therapies Andrew Pipe, CM, MD Chief, Division of Prevention & Rehabilitation University of Ottawa Heart Institute Faculty/Presenter Disclosure Andrew Pipe,
More informationObjectives. Disclosure. Prevalence of Tobacco Use. Smoking Cessation Pharmacotherapy 3/2/2016.
Smoking Cessation Pharmacotherapy Melodie Merzier-Michel PGY-1 Pharmacy Resident Memorial Regional Hospital www.fshp.org Objectives Discuss the prevalence of tobacco use in the United States (U.S.) Describe
More informationSmoking Cessation for Persons with Serious Mental Illness
Smoking Cessation for Persons with Serious Mental Illness MDQuit Best Practices Conference January 22, 2009 Faith Dickerson, Ph.D., M.P.H. Sheppard Pratt Health System Lisa Dixon, M.D., M.P.H. Melanie
More informationSmoking Cessation Strategies in 2017
Smoking Cessation Strategies in 2017 Robert Schilz DO, PhD, FCCP Division of Pulmonary, Critical Care and Sleep Medicine Director of Lug Transplantation University Hospitals of Cleveland Case Western University
More informationMonth/Year of Review: March 2014 Date of Last Review: April 2012
Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119 Copyright 2012 Oregon State University. All Rights
More informationBreaking the Chains of Nicotine Dependence - A Breakthrough Approach
Breaking the Chains of Nicotine Dependence - A Breakthrough Approach Dr Rob Young Senior Lecturer & Consultant Physician Auckland Hospital, New Zealand Smoking Cessation in 2001 Smoking contributes to
More informationLearning Objectives- Pharmacists
Tobacco Cessation & Motivational Interviewing: Connecting Patients to Quit Annie Ottney, PharmD, BCPS, CTTS Learning Objectives- Pharmacists Describe the current burden of tobacco abuse in the United States
More informationAdolescents and Tobacco Cessation
Adolescents and Tobacco Cessation Jonathan D. Klein, MD, MPH American Academy of Pediatrics Julius B. Richmond Center and the University of Rochester Rochester, NY Goal To review current evidence and perspectives
More informationNicotine Replacement and Smoking Cessation: Update on Best Practices
Nicotine Replacement and Smoking Cessation: Update on Best Practices Adrienne Duckworth, MSN, APRN, FNP-C, CTTS Section of Hematology/Oncology WVU Department of Medicine WVU Cancer Institute Objective
More informationSmoking Cessation A Clinicians Perspective. Jeff Wilson, MD
Smoking Cessation A Clinicians Perspective Jeff Wilson, MD Overview Tobacco control what we have accomplished and the road ahead Role of the health care professional Using pharmacotherapy Electronic cigarettes
More informationSmoking Cessation: Treating Tobacco Dependence
Smoking Cessation: Treating Tobacco Dependence Pat Folan, RN Center for Tobacco Control Pulmonary Medicine NS-LIJ Health System NYS DOH Tobacco Control Program Treating Tobacco Dependence Center for Tobacco
More informationUPDATE TREATMENT OF TOBACCO USE DISORDERS
Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences UPDATE TREATMENT OF TOBACCO USE DISORDERS MARK DUNCAN MD UNIVERSITY OF WASHINGTON OBJECTIVES 1. Remind everyone
More informationEMERGING ISSUES IN SMOKING CESSATION
EMERGING ISSUES IN SMOKING CESSATION Andrew Pipe, CM, MD Chief, Division of Prevention & Rehabilitation University of Ottawa Heart Institute Faculty/Presenter Disclosure Andrew Pipe, CM, MD University
More information9/16/2016. I would feel comfortable dispensing/prescribing varenicline to a patient with a mental health disorder. Learning Objectives
The Smoking Gun: for Smoking Cessation in Patients with Mental Health Disorders BRENDON HOGAN, PHARMD PGY2 PSYCHIATRIC PHARMACY RESIDENT CTVHCS, TEMPLE, TX 09/23/2016 I would feel comfortable dispensing/prescribing
More informationVarenicline and Other Pharmacotherapies for Tobacco Dependence
Varenicline and Other Pharmacotherapies for Tobacco Dependence J. Taylor Hays, M.D. Associate Director Nicotine Dependence Center Mayo Clinic 2012 MFMER slide-1 Learning Objectives Understand the mechanism
More informationKicking the Habit Pharmacological Help for Smokers
Kicking the Habit Pharmacological Help for Smokers Catherine E. Cooke, PharmD, BCPS, PAHM Independent Consultant Clinical Assistant Professor, Univ. of Maryland Special Thanks to Teisha Robertson, PharmD
More informationAll forms of. tobacco. Percent. are harmful.
t TRAINING OVERVIEW Rx for CHANGE Clinician-Assisted Tobacco Cessation for Surgical Patients Epidemiology of Tobacco Use Benefits e of Qutt Quitting for Surgical gca Patients ate ts Tobacco Dependence
More informationButt in to Butt Out- Pharmacist led clinical model for managing nicotine dependency
Butt in to Butt Out- Pharmacist led clinical model for managing nicotine dependency Emma Dean Acting Population Health and Health Promotion Coordinator Alfred Health Wednesday 30 th May 2018 2 Disclosures
More informationSmoking Cessation Treatment for Adolescents
Review Article Smoking Cessation Treatment for Adolescents Julie P. Karpinski, PharmD, 1 Erin M. Timpe, PharmD, 2 and Lisa Lubsch, PharmD 2 1 Department of Pharmacy Practice, Concordia University Wisconsin,
More informationUpdates in the Treatment of Tobacco Use Disorder
Updates in the Treatment of Tobacco Use Disorder PCSS-MAT; Smoking Cessation Leadership Center and American Psychiatric Association Jill M Williams, MD Professor Psychiatry Director, Division Addiction
More informationTREATMENT INTERVENTIONS
SMOKING CESSATION TREATMENT INTERVENTIONS Smoking and Health Tobacco is the single most preventable cause of death in the world today. kills more than five million people By 2030, the death toll will exceed
More informationSave a Life in 3 Minutes
Save a Life in 3 Minutes Tobacco Cessation for Dental Hygiene Care Produced by Margaret J. Fehrenbach, RDH, MS 1 Not since the polio vaccine has this nation had a better opportunity to make a significant
More informationELECTRONIC CIGARETTES WHAT S THE BOTTOM LINE?
ELECTRONIC CIGARETTES WHAT S THE BOTTOM LINE? E-cigarettes have the potential to benefit adult smokers who are not pregnant if used as a complete substitute for regular cigarettes and other smoked tobacco
More informationPage 1 of 7 INITIAL EVALUATION MANAGEMENT. STATUS Yes. See page 2. Refer patient to a tobacco treatment program 3 (preferred) Patient interested?
Page 1 of 7 INITIAL EVALUATION Screen current tobacco use status Has patient smoked more than 100 cigarettes in lifetime? Has patient smoked or used tobacco in the last 12 months? STATUS Within the last
More informationSmoking Cessation. Disclosures. Thank You. None
Smoking Cessation Dr. Jamie Kellar; BSc, BScPhm, PharmD Clinician Educator Centre for Addiction and Mental Health Assistant Professor Leslie Dan Faculty of Pharmacy Disclosures None Thank You Several slides
More informationVarenicline and cardiovascular and neuropsychiatric events: Do Benefits outweigh risks?
Varenicline and cardiovascular and neuropsychiatric events: Do Benefits outweigh risks? Sonal Singh M.D., M.P.H, Johns Hopkins University Presented by: Sonal Singh, MD MPH September 19, 2012 1 CONFLICTS
More informationDERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC)
DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) Derbyshire Formulary for Nicotine Replacement Therapy (NRT) 1. Supporting Smokers to stop smoking The most effective method to quit smoking is by quitting
More informationConsultant. patient care through drug education
The Improving Consultant patient care through drug education December 2017 Volume XXVI Number 11 Smoking Cessation For the Busy Clinician 2 Robin L. Corelli, PharmD, Lisa A. Kroon, PharmD and Karen S.
More informationNicotine Replacement Therapy, Zyban and Champix. Name of presentation
Nicotine Replacement Therapy, Zyban and Champix Nicotine Replacement Therapy (NRT) - Rationale for use Nicotine is highly addictive and causes unpleasant withdrawal symptoms which often undermine a quit
More informationDrug Use Evaluation: Smoking Cessation
Drug Use Research & Management Program Oregon State University, 3303 SW Bond Av CH12C, Portland, Oregon 97239-4501 Phone 503-947-5220 Fax 503-494-1082 Drug Use Evaluation: Smoking Cessation Tobacco cessation
More informationTobacco use assessment, brief counseling,, and quit line referral
Tobacco use assessment, brief counseling,, and quit line referral What is the evidence for tobacco cessation counseling? Tobacco use is the leading cause of preventable death in the US 1 Counseling and
More informationSmoking Cessation Strategies: What Works?
Smoking Cessation Strategies: What Works? Andrew M. Busch, Ph.D. Centers For Behavioral and Preventive Medicine The Miriam Hospital Department of Psychiatry and Human Behavior Alpert Medical School of
More informationChantix (Varenicline) and Risk of Cardiovascular Events
PL Detail-Document #270803 This PL Detail-Document gives subscribers additional insight related to the Recommendations published in PHARMACIST S LETTER / PRESCRIBER S LETTER August 2011 Chantix (Varenicline)
More informationPhil Mohler, M.D Crossroads Blvd P.O. Box Grand Junction, CO July 2016
Phil Mohler, M.D. phil.mohler@rmhp.org 2775 Crossroads Blvd P.O. Box 10600 Grand Junction, CO 81502-5600 Avoid these expensive me-too drugs: Intermezzo Vimovo Livalo Pristiq Viibyrd Edarbi Daliresp July
More informationIntegrating Tobacco Cessation into Practice
Integrating Tobacco Cessation into Practice Presented To Smoking Cessation Leadership Center PIONEERS FOR SMOKING CESSATION CAMPAIGN By Carol Southard, RN, MSN Tobacco Treatment Specialist Northwestern
More informationAbbreviated Class Review: Tobacco Cessation Medications. Bupropion sustained -release Varenicline (Chantix )
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationTobacco treatment for people with serious mental illness (SMI)
Tobacco treatment for people with serious mental illness (SMI) An opportunity to close the mortality gap Massachusetts Mental Health Center 1 National Resource Center for Academic Detailing A compelling
More information